A Call for Pharmacogenovigilance and Rapid Falsification in the Age of Big Data: Why not First Road Test Your Biomarker?

Biomarkers Definitions Working Group. (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther, 69, 89–95.

Dereli T , Coşkun Y , Kolker E , Güner O , Ağırbaşlı M , and Özdemir V . (2014). Big data and ethics review for health systems research in LMICs: Understanding risk, uncertainty and ignorance—and catching the black swans?. Am J Bioeth, 14, 48–50.

IJzerman MJ , and Steuten LM . (2011). Early assessment of medical technologies to inform product development and market access: A review of methods and applications. Appl Health Econ Health Policy, 9, 331–347.

Kalow W , Özdemir V , Tang BK , Tothfalusi L , and Endrenyi L . (1999). The science of pharmacological variability: An essay. Clin Pharmacol Ther, 66, 445–447.

Kampourakis K , Vayena E , Mitropoulou C , van Schaik RH , Cooper DN , Borg J , and Patrinos GP . (2014). Key challenges for next-generation pharmacogenomics. EMBO Rep, 15, 472–476.

Ladewski LA , Belknap SM , Nebeker JR , et al. (2003). Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: First results from the research on adverse drug events and reports project. J Clin Oncol, 21, 3859–3866.

Mizzi C , Peters B , Mitropoulou C , et al. (2014). Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics, 15, 1223–1234.

Özdemir V , Kolker E , Hotez PJ , et al. (2014). Ready to put metadata on the post-2015 development agenda? Linking data publications to responsible innovation and science diplomacy. OMICS, 18, 1–9.

Özdemir V , and Lerer B . (2005). Pharmacogenomics and the promise of personalized medicine. In: Pharmacogenomics, Second Expanded Edition. Kalow W , Meyer UA , Tyndale RF . (Editors). New York: Francis & Taylor, pp. 13–50.

Scedil;ardaş S . (2010). Pharmacogenovigilance–An idea whose time has come. Curr Pharmacogenomics Person Med, 8, 1–3. Available from: http://www.farmakovijilansdernegi.org/UserFiles/File/Pharmacogenovigilance.pdf. Last access: October 20, 2014.

Steuten LM , and Ramsey SD . (2014). Improving early cycle economic evaluation of diagnostic technologies. Expert Rev Pharmacoecon Outcomes Res, 14, 491–498.

Warnich L , Drögemöller BI , Pepper MS , Dandara C , and Wright GE . (2011). Pharmacogenomic research in South Africa: Lessons learned and future opportunities in the Rainbow Nation. Curr Pharmacogenomics Person Med, 9, 191–207.